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Summary 
End-stage kidney disease (ESKD), the most severe form of chronic kidney disease, results in 
a high health and economic burden for patients, families and communities. It usually 
requires kidney replacement therapy (KRT) in the form of dialysis or kidney transplantation 
for patients to survive. The number of people receiving KRT treatment for ESKD has tripled 
between 1991 and 2011.  
This report examines whether the number of people with treated-ESKD (prevalence) will 
continue to increase up until 2020. This information is important for health service planning 
and resource allocation in the future. It is important to note that projections are not intended 
to function as exact forecasts, but to give an indication of what might be expected if the 
stated assumptions were to apply over the projection time frame and so should be 
interpreted with this in mind. 
The projected treated-ESKD prevalence estimates were derived from a series of models, to 
provide a range of projection results. The report also examines the influence of diabetes on 
future treated-ESKD prevalence growth. 
Prevalence of treated-ESKD is increasing 
• The number of people receiving KRT for their ESKD is projected to increase over the 
next decade. The ‘base’ model predicts that the prevalence will rise by 60%—from 19,780 
cases in 2011 to 31,589 cases in 2020. This is despite the Australian population only 
increasing 13% over this period (ABS 2013a). 
• The projected increase in treated-ESKD is expected to occur across all age groups, with 
the largest increase occurring for people who start treatment when they are over 75, 
where the prevalence is projected to double from 2,013 to 4,130 cases. 
• When the rate of new cases of treated-ESKD is held constant, the prevalence of treated-
ESKD is projected to increase by 45% (rising to 28,756 cases). Where dialysis survival is 
expected to improve over the projections years, the prevalence is expected to increase by 
64% (rising to 32,437 cases). 
Diabetes to continue to contribute to increases in treated-ESKD 
• The prevalence of treated-ESKD with diabetes as a primary cause is projected to double 
between 2011 and 2020 (from 4,392 to 9,677 cases). By contrast, the prevalence of treated-
ESKD without diabetes as the primary cause is projected to increase by 47% (from 15,388 
to 22,960 cases). 
Dialysis- and transplant-treated-ESKD cases are projected to 
increase 
• The number of dialysis-treated ESKD patients is projected to increase by 49%—from 
10,998 cases in 2011 to 16,362 cases in 2020, while the number of transplant-treated 
patients is projected to rise by 73%—from 8,782 cases in 2011 to 15,227 cases in 2020. 
• In 2020, almost half (48%) of all treated-ESKD patients are predicted to have a 
functioning kidney transplant. This compares with 44% in 2011. 
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1 Introduction 
Chronic kidney disease (CKD) is a common chronic disease in Australia, with around 1 in 10 
Australians showing biomedical signs of CKD (ABS 2013b). CKD refers to all kidney 
conditions where a person has evidence of kidney damage and/or reduced kidney function, 
lasting at least 3 months. Many people do not know that they have kidney disease as up to 
90% of kidney function can be lost before symptoms appear. Clinically, CKD is classified into 
five stages, from kidney damage with no loss of kidney function to severe loss of kidney 
function. However, it is often not until kidney function has deteriorated into the fifth and 
most severe stage, known as end-stage kidney disease (ESKD), that a diagnosis is made. 
For people with ESKD, kidney function has deteriorated to such an extent it is no longer 
sufficient to sustain life. Kidney replacement therapy (KRT) is required for the patient to 
survive, either in the form of kidney transplantation (in which a kidney from either a living 
or recently deceased donor is implanted in a patient), or by dialysis (an artificial way of 
removing waste substances from the blood provided largely in hospitals or satellite dialysis 
units, but also in a home setting [Kidney Health Australia 2007]). However, not all patients 
with ESKD receive KRT. Prognosis, anticipated quality of life (with or without KRT), 
treatment burden on the patient, and patient preference all play a part in the decision for or 
against KRT (Murtagh et al. 2007). See Appendix A for more information on the treatment of 
ESKD. 
The health and economic burden of ESKD on individual patients, carers and the community 
is high. At the end of 2011, there were around 19,800 people receiving KRT for their ESKD 
(referred to as treated-ESKD hereafter) and over 2,500 new cases of treated-ESKD in 2011 
(ANZDATA 2013). Rates of treated-ESKD are high among certain groups of the population, 
including older Australians (rates are 6 times as high among those aged 70 years and over 
compared with those under 50 years) and among Aboriginal and Torres Strait Islander 
people (where rates of treated-ESKD are 6 times the rate of non-Indigenous Australians). 
CKD is also a costly disease, accounting for around 1.7% of total allocated health care 
expenditure in 2004–05, with KRT responsible for most (85%) of that expenditure. The cost of 
dialysis treatment is high, ranging from $101,189 per patient per year for in-centre treatment 
to $54,017 per patient year for community/home self-care haemodialysis, according to a 
costing study funded by NSW Health (New South Wales Government 2009). 
ESKD places a considerable health, time and cost burden on patients and families (Low et al. 
2008), including reduced life expectancy (Turin et al. 2012), reduced quality of life (Dobbels 
et al. 2007; Lew & Piraino 2005), and significant out-of-pocket expenses (New South Wales 
Government 2009). Further, the need to adhere to strict treatment protocols and the need for 
frequent treatment for dialysis patients—normally 4–5 hour sessions 3 times per week for in-
centre dialysis—often impacts on education, employment and family responsibilities, and 
often results in the need to relocate to access dialysis (Preston-Thomas et al. 2007).  
However, ESKD is largely a preventable chronic condition, as many of its risk factors are 
modifiable, including high blood pressure, tobacco smoking, physical inactivity, poor 
nutrition, and obesity. Many of the risk factors for CKD also apply to other chronic diseases 
such as cardiovascular disease and diabetes which, in turn, are risk factors for ESKD. 
Diabetes is the leading cause of treated-ESKD in Australia, accounting for one-in-three new 
cases in 2011. Cardiovascular disease, especially hypertension, is also one of the major causes 
of treated-ESKD (ANZDATA 2013). 
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The number of people receiving KRT treatment for ESKD has tripled over the last two 
decades, increasing from around 6,600 to 19,800 between 1991 and 2011. This increase is in 
part attributed to increases in diabetes prevalence (see Box 1.1) that have led to increases in 
diabetic nephropathy and consequently ESKD; increases in the prevalence of high blood 
pressure; better survival rates for patients on KRT; and a reduction in the number of people 
dying from cardiovascular diseases (McDonald et al. 2005; Stewart et al. 2004). Over the past 
few decades progressively greater numbers of older people are also being treated for ESKD 
(AIHW 2009), meaning that previously untreated-ESKD cases are now contributing to higher 
treated-ESKD prevalence counts.  
It is anticipated that the prevalence of treated-ESKD will continue to increase in Australia 
over the next decade, due in part to the ageing population and increasing rates of diabetes; a 
finding that has been predicted by other studies (Cass et al. 2010). Not all ESKD patients are 
treated with KRT, so it is important to note that the prevalence of treated-ESKD is not only 
determined by the prevalence of the disease itself, but is also influenced by patient choice, 
and by KRT acceptance policies. It is possible that changes in either treatment availability or 
acceptance policies over the next decade may influence future treated-ESKD prevalence 
rates.  
This report is a follow-on report from a previous AIHW project that presented projections of 
the incidence of treated-ESKD (AIHW 2011b). This report explores the future burden of 
ESKD in Australia by presenting projections of the prevalence of ESKD for patients who 
receive KRT for the period 2012 to 2020, based on data from the Australian and New Zealand 
Dialysis and Transplant (ANZDATA) Registry.  
Projections are, by their nature, estimates about what might reasonably be expected in the 
future. Predicting the future prevalence and incidence (see Box 1.1) of treated-ESKD is 
important for dialysis and kidney transplant-related health service planning and resource 
allocation purposes. 
Box 1.1 Definitions of incidence and prevalence  
Incidence refers to the number of new cases (of an illness, disease or event) occurring during 
a given period. Treated-ESKD patients are only classified as being ‘incident’ once. 
Prevalence refers to the number or proportion of cases or instances present in a population at 
a given time. The prevalence of treated-ESKD is related to both the incidence of the disease 
and how long people live while receiving KRT (survival). The prevalence is also influenced 
by factors not related to ESKD itself, for example, patient choice regarding KRT.  
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2 Methods 
This chapter describes the data sources used in the prevalence projections, and the range of 
models used for projecting the prevalence of ESKD. It describes the construction of the ‘base’ 
treated-ESKD prevalence projections model to 2020, as well as the assumptions of the 
various models and data challenges and limitations. The need for alternative projection 
models and a description of these alternative models is also provided.  
Data sources 
Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry 
The data used in projecting the prevalence of ESKD were based on Australian and New 
Zealand Dialysis and Transplant (ANZDATA) Registry data. This registry collects 
information from all dialysis and transplant units in Australia and New Zealand as at 
31 December each year, and these data are published annually (see <www.anzdata.org.au>). 
The ANZDATA Registry includes the number of people for whom the intention to treat is 
long-term; those who start dialysis or transplant treatment for ESKD (incident treated-ESKD 
cases; that is, new cases of treated-ESKD) during each calendar year; and the total number of 
(prevalent) treated-ESKD cases at the end of each calendar year. ANZDATA also records 
other information such as age, sex, treatment type, comorbidities, and Indigenous status. All 
relevant hospitals and related dialysis units participate. While patients have the option of 
opting-out of having part or all of their data recorded, this rarely happens. ANZDATA 
incidence and prevalence data were both required for projecting the prevalence of treated-
ESKD.  
The interpretation and reporting of ANZDATA Registry information in this report have been 
undertaken by the AIHW, and do not represent ANZDATA Registry policy or interpretation. 
Information about the data quality of ANZDATA can be found in the 35th Annual 
ANZDATA Report 2012 <http://www.anzdata.org.au/v1/report_2012.html>. 
Population data 
The latest ABS population projection series (ABS 2013a) were used in projecting the number 
of future incident cases of treated-ESKD for each year over the projection period 2012 to 
2020. These incident counts were inputs for the prevalence projections models. The ABS 
population projections reveal the size, structure and distribution of the future population 
under various assumptions on future levels of fertility, mortality and migration. These 
assumptions are based on long- and short-term trends and future scenarios dictated by 
research in Australia and elsewhere (ABS 2013a). After each census, the ABS produce three 
series of projections (Series A, B and C), which provide a range of projections for analysis 
and discussion. Series B—the medium-variant projection—is the one used for the incidence-
projections component in the prevalence model.  
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Construction of ‘base’ prevalence projections model 
The construction of ‘base’ prevalence projections model involved two broad stages:  
• projection of the incidence of dialysis- and transplant-treated-ESKD cases based on 
ANZDATA Registry data from 1996 to 2011. 
• follow-up of these projected incident cases and existing prevalent cases to 2020.  
Similar modelling techniques were used in other treated-ESKD prevalence projections (Cass 
et al. 2010; Cass et al. 2006; Department of Health and Ageing (DoHA) 2011). (See Appendix 
B and D for more detailed information on the construction of the prevalence models.) 
A flow chart of the different elements of the ‘base’ prevalence projections overall model, and 
of the data making up these components, is shown in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The prevalence projections methodology is explained in detail in Appendix B. 
(a) Data sources used in model construction. 
(b) Inputs for prevalence projections model component. 
(c) Output for prevalence projections model component. 
Figure 2.1: Prevalence projection model components, data sources, inputs and outputs 
Incidence projections 
The incidence projections used in the ‘base’ prevalence projections model were based on 
existing ANZDATA registry trends in the incidence of treated-ESKD in Australia. The 
number of incident dialysis- and transplant-treated-ESKD cases were projected using the 
log-linear Poisson regression methodology that was previously used by the AIHW for 
projecting the incidence of treated-ESKD (AIHW 2011b).  
The incidence projections model used in this report extrapolates existing treated-ESKD 
incidence rates into the projection years; applies these rates to the ABS Series B population 
projections (ABS 2013a) to calculate incident counts; and then estimates incident dialysis- 
and transplant-treated-ESKD incident counts from these numbers (see Appendix B). 
Incidence projections were stratified by sex, and these projection counts were summed 
together to create person-level counts. Incidence projections were created for 5 age groups 
Incidence projections 
Data sources(a): 
• ANZDATA incidence data. 
• ABS population projections 
Inputs(b): 
• Existing ANZDATA incidence 
data 
Outputs(c): 
• Projected dialysis- and 
transplant-treated incident 
counts. 
 
 
Follow-up of cases 
Data sources(a): 
• ANZDATA prevalence data 
Inputs(b): 
• Existing ANZDATA prevalence 
data  
• Projected dialysis- and 
transplant-treated counts 
Outputs(c): 
• Projected prevalence counts. 
 
 
 
      
    
  
    
    
 
  Projections of the prevalence of treated end-stage kidney disease in Australia 5 
(0–29, 30–49, 50–64, 65–74 and 75-and-above). Projected incident counts from 2012 to 2020 are 
listed in tables E1 and E2. 
Follow-up of projected incident cases and existing prevalent cases 
The ‘base’ prevalence projection model in this report expands on the previous AIHW 
treated-ESKD incidence projections model by using Markov modelling techniques to follow 
up existing prevalent cases and projected incident cases to predict the future prevalence of 
treated-ESKD.  
Markov models are capable of modelling clinical conditions when risk is continuous over 
time. Markov models assume that a patient is always in one of a finite number of states 
(referred to as Markov states). All events of interest are modelled as transitions from one 
state to another (Sonnenberg & Beck 1993); for example, from dialysis to death or from 
transplant to dialysis. 
The Markov model component of the ‘base’ prevalence projection model (to be referred to as 
the ‘base’ model) was stratified by the following factors: 
• treatment length 
• treatment modality (dialysis or transplant) 
• incident age.  
Existing prevalent cases and projected incident cases were followed through the projection 
years using a ‘base’ model that consisted of 5 separate Markov models. These Markov 
models had the same overall structure, although they had different incident age cases 
feeding into them (age groups 0–29, 30–49, 50–64, 65–74 and 75-and-above). The ‘base’ model 
was based on incident age, rather than current age, as the projection methods used in this 
report do not allow for patients to move between the 5 Markov models as the age over the 
projection period. 
These models incorporated transfers between dialysis, transplant and death; that is, 3 
possible states, and 6 possible transitions between these states: dialysis to death; transplant 
to death; transplant to dialysis; dialysis to transplant; remaining on dialysis; or remaining 
with a functioning transplant (see Figure B1).  
The likelihood of transitioning between treatment states depends on transition probabilities. 
The transition probabilities for the 5 different Markov cycles in each incident age group 
model were based on the latest trends in KRT treatment outcomes. The latest treatment 
trends were assessed by following a cohort of patients who were prevalent in 2009–2011 and 
calculating average transition probabilities for this period. (See ‘Prevalence model 
construction’ in Appendix B for more detailed information on the prevalence projections 
model structure and construction.) 
The influence of diabetes on future prevalence counts 
The ‘base’ model was also altered to assess the influence of diabetes on future treated-ESKD 
prevalence counts. This involved separately projecting the prevalence of treated-ESKD for 
patients with, and without, diabetes as a primary cause of their treated-ESKD.  
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Projection assumptions 
The accuracy of prevalence projections depends on the accuracy of the available historical 
data; the suitability of the model used as a representation of the underlying trends; and the 
assumptions underpinning the model. The assumptions for the ‘base’ projections model are 
best conceptualised by looking separately at the two main components of the model: 
incidence projections; and the follow-up of cases. (Note that some assumptions cross over 
between these two components.) 
Incidence projections 
The incidence projections were based on the following assumptions: 
• recent historical trends (1996–2011) in the incidence of treated-ESKD will continue in the 
projection years 
• the proportion of incident cases that receive a transplant before starting dialysis 
treatment (pre-emptive transplantation) will remain constant over the projection years 
• the population will grow and age according to the Series B ABS population (medium 
variant) projections for the next decade (see ‘Population data’ on page 3) 
• treatment options, patient choices, and availability of services will remain unchanged in 
the projection years. 
The follow-up cases over the projection period 
The follow-up of prevalent cases over the projection period was based on the following 
assumptions: 
• transplant outcomes do not vary by transplant type (donations from deceased versus 
living donors) or by transplant number (first transplant, second transplant, and so forth) 
• dialysis treatment outcomes do not vary by dialysis modality (peritoneal dialysis versus 
haemodialysis) or by dialysis location (home, hospital or satellite dialysis unit) (see 
Appendix A for a discussion of these terms) 
• transition probabilities in each incident age treatment length group will remain constant 
over the projection years. For example, the likelihood of receiving a transplant while on 
dialysis (dialysis to transplant transition) remains constant across the projection years 
• only a patient’s current treatment state (dialysis or transplant), their incident age and 
their KRT treatment length influence their transition probabilities 
• transition probabilities remain constant after 5 years of treatment. For example, over the 
projection years, all patients in a given incident age group who have received KRT for 
over 5 years have the same likelihood of receiving a transplant 
• the average treatment patterns (in the form of transition probabilities) that occurred in 
2009–2011 will continue throughout the projection years. (For example, for patients with 
a given treatment length and incident age group, the likelihood of remaining on dialysis, 
or of receiving a transplant, remains constant over the projection years)  
• patients can only transition once between Markov states (dialysis, transplant or death) 
during a Markov cycle (1 year) 
• treatment options, patient choices, and availability of services will remain unchanged in 
the projection years. 
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Variables controlled for in ‘base’ prevalence 
projections model 
Numerous variables are likely to influence the future prevalence of treated-ESKD. 
The ‘base’ prevalence projections model used in this report controlled for some of these 
factors, including: 
• the age profile and size of the future Australian population 
– The incidence of treated-ESKD is related to age. An ageing population is likely to 
contribute to an increase in incidence of treated-ESKD, which in turn will lead to an 
increase in the prevalence of treated-ESKD (assuming survival rates do not worsen). 
The incidence component of the prevalence projections used ABS population 
projections to account for likely changes in prevalence counts due to changes to the 
population size and age structure.  
• sex-related differences in incidence rates 
– Males have higher incidence and prevalence rates of treated-ESKD. Projections of the 
incidence of treated-ESKD were carried out separately for males and females, with 
these results summed to create person counts for each age group for each projection 
year.  
• select KRT treatment states 
– Transplant-treated-ESKD patients tend to have improved survival relative to 
dialysis-treated patients. The Markov-model-based component of the ‘base’ model 
controlled for differences in survival between dialysis- and transplant-treated cases. 
• age and treatment duration related effects 
– Age and KRT treatment duration also influence transition probabilities. For example, 
older dialysis patients are less likely to receive a transplant (dialysis-to-transplant 
transition) during a Markov cycle (1 year). The Markov model controlled for age and 
KRT treatment duration by having separate Markov models based on incident age 
and separate cycles within these. 
Data limitations 
Projections are, by nature, estimates about what might reasonably be expected in the future. 
A number of statistical modelling approaches have been developed and widely applied in 
recent decades. The choice of a good modelling approach, based on historical trends and 
other available information, can generate the best estimates. However, there is no guarantee 
of their realisation in the future. 
As noted above, the prevalence model used in this report is made up of two main 
components: projecting the incidence of treated-ESKD, and the follow-up of new and 
existing treated-ESKD cases. Both these components involve several assumptions and both 
have potential sources of error. 
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In developing these assumptions, a balance needed to be achieved between realistic model 
assumptions, model complexity, model stability and data availability and reliability. 
Variables not controlled for in the projections model 
Several factors were not controlled for in the projections model that may influence future 
prevalence rates of treated-ESKD. These factors include: comorbid conditions (excluding 
diabetes as a primary cause); KRT treatment history; transplant type (living versus deceased 
donor source); dialysis type; and ethnicity. KRT treatment policies are also likely to influence 
future prevalence of treated-ESKD.  
Some of these factors are potentially able to be factored into the ‘base’ prevalence projections, 
but these were not controlled for in the model (see Projection Assumptions, above). When 
controlling for factors in the model, there is a need to balance having realistic projection 
assumptions with model complexity and stability. Stratifying the projections model too 
finely is likely to lead to unstable and potentially inaccurate projection results. For example, 
although treatment patterns (transition probabilities) do vary slightly by sex, the Markov 
model component of the projections model was not stratified by sex, as this would have led 
to less stable transition probabilities and therefore less stable projection results. 
Indigenous projections 
The prevalence of treated-ESKD is high among Aboriginal and Torres Strait Islander 
people—at the end of 2011, almost 8% of people with treated-ESKD commencing KRT 
identified as Indigenous, despite making up only 3% of the total Australian population. 
Furthermore, Indigenous Australians with ESKD were far less likely than their non-
Indigenous counterparts to be treated with a functioning kidney transplant in 2011 (13% 
compared with 47%, respectively) (ANZDATA 2013).  
Unfortunately the projections model was not able to control for Indigenous status, due to the 
relatively small numbers of Indigenous Australians with treated-ESKD in the ANZDATA 
Registry for stable Markov modelling. These small cell sizes impact on the reliability and 
robustness of the Indigenous-specific transition probabilities, meaning that other aspects of 
the projections model would need to be altered to calculate stable transition probabilities (for 
example, the model would have to be stratified by fewer incident age groups).  
At the time of preparing this publication, there was also a lack of up-to-date Indigenous 
population projection data: the latest Indigenous population projections are based on the 
2006 Census, rather than the 2011 Census-based Series B total population estimates, which 
were used in the ‘base’ prevalence projections model. 
Alternative models 
Appendix C contains an assessment of the accuracy of the two main components of the ‘base’ 
prevalence projections model: the incidence model and the Markov model for following up 
cases over the projection period. Following this assessment, two alternative prevalence 
models were constructed that involve slightly different projection assumptions to the ‘base’ 
model. (See Appendix D for more detailed information on these alternative models.) A 
summary of the 3 models used in this report is also listed in Table 2.1. 
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‘Stable incidence’ model 
The incidence model-fit analysis, presented in Figures C1–6 in Appendix C, appears to 
suggest that the incidence model component of the ‘base’ prevalence projections model may 
overestimate the incidence of treated-ESKD, particularly for older patients (the 75-and-over 
incident age group). This overestimation in future incident counts is likely to be due to the 
incidence model not controlling for the recent (2008–2011) stabilisation of treated-ESKD 
incidence trends (see Figure E1). 
The ‘stable incidence’ model was created to control for any potential overestimation of the 
future incidence (and prevalence) of treated-ESKD due to a possible sustained (2012–2020) 
levelling off of future treated-ESKD incidence trends. The model assumes that the 2008–2011 
trends in the incidence of treated-ESKD (see Figure E1) remain constant over the projection 
years. All other aspects of the model remained the same as the ‘base’ projections model. The 
‘stable incidence’ model is a more conservative estimate of future prevalence counts.  
‘Improving dialysis treatment outcomes’ model  
Markov model-fit analysis (Figure C7) suggests that the Markov model component of the 
projections model may underestimate prevalence for older incident age patients (age groups 
65–74 and 75-and-above). 
These results suggest that the assumptions underpinning the ‘base’ model for following up 
existing prevalent cases lead to an underestimation in projection results in older incident age 
groups (ages 65–74 and 75-and-above), assuming that similar treatment and incidence trends 
that occurred from 2003 to 2011 also occur from 2012 to 2020.  
For older patients, the assumption most likely to be disproven is that treatment outcomes 
(transition probabilities) remain constant over the projection years. In particular, over the last 
decade there has been an improvement in dialysis survival for older patients (that is, a 
decrease in dialysis-death transition probabilities) (see Figure C8). 
The ‘improving dialysis treatment outcomes’ model attempted to factor in improving 
dialysis treatment outcomes for older patients by altering the dialysis-death and dialysis-
dialysis transition probabilities in the ‘base’ model for older patients (age groups 65–74 and 
75-and-above) over the projection years. This involved using the previous trends in dialysis 
survival (dialysis-death transition probabilities) to predict improvements in dialysis survival 
over the projection years. All other aspects of the model remained the same as for the ‘base’ 
projections model. 
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Table 2.1: Summary of prevalence projections models  
Model name Description Chapter 
‘Base’ model 
• Assumes that the 1996 to 2011 trend in treated-ESKD 
incidence will continue over the projection years 
• Uses Markov modelling techniques to follow treated-
ESKD patients over the projection years 
• Assumes that recent KRT treatment outcomes  
(2009–2011) will continue over the projection years.  
Chapter 3 
Diabetes projections • ‘Base’ model stratified by treated-ESKD cases with and 
without diabetes as a primary cause of treated-ESKD. 
End of Chapter 3 
‘Stable incidence’ model 
• Assumes the 2008–2011 (‘stable’) trends in the 
incidence of treated-ESKD will remain constant over the 
projection years  
• All other aspects of the model remained the same as the 
‘base’ projections model 
• Produces conservative estimates of the future 
prevalence relative to the ‘base’ model. 
Chapter 4 
‘Improving dialysis treatment 
outcomes’ model 
• Assumes recent improvements in dialysis survival for 
older patients (incident age groups 65–74 and 75-and-
above) will continue over the projection years  
• All other aspects of the model remained the same as the 
‘base’ projections model 
• Gives a less conservative estimate of the future 
prevalence relative to the ‘base’ model. 
Chapter 4 
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3 Base prevalence projections model 
This chapter presents the results of the ‘base’ prevalence projections model to determine 
whether the recent increase in treated-ESKD prevalence is likely to continue in the future. It 
also examines prevalence projections for dialysis and transplantation separately, and the 
influence of diabetes on the future prevalence of treated-ESKD. 
Overall 
The ‘base’ model shows a continued increase in the prevalence of treated-ESKD, increasing 
60% from 19,780 cases in 2011 to 31,589 cases in 2020 (Figure 3.1). This is consistent with the 
existing trend for treated-ESKD prevalence both in Australia and internationally (U.S. Renal 
Data System 2013). 
The increase in treated-ESKD prevalence is projected to occur across all incident age groups, 
with larger increases occurring in the older age groups. The prevalence of treated-ESKD 
among those aged 75 years and over is expected to more than double between 2011 to 2020 
(increasing from 2,013 to 4,130), while among the 0–29 incident age group the rate of increase 
was considerably slower and is projected to increase by 27% over this period (Figure 3.1). 
This pattern is consistent with the rapid increase observed in the prevalence and incidence of 
ESKD in the 75-and-over age group over the last 20 years, due partly to an increasing trend 
to treat older patients (AIHW 2011b). 
There are a number of likely contributing factors for the projected increase in the prevalence 
of treated-ESKD, including increases in the population size and the ageing of the population; 
improved survival rates for patients with treated-ESKD; and increasing incidence rates for 
treated-ESKD—in part due to the increasing prevalence of diabetes in Australia (see 
Figure 3.3).  
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Notes 
1. The solid lines represent existing registry data while the dotted lines are for projected prevalent cases. 
2. The percentage increases from 2011 to 2020 for each age group and for total cases are listed in the legends. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure 3.1: Prevalence of registered and projected treated-ESKD, for all patients and by incident 
age, 2003–2020 
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Kidney replacement therapy (KRT) treatment trends 
Examining dialysis and transplant cases separately over the projection years allows for a 
better prediction of future service-delivery needs, assuming the prevalence projection 
assumptions are accurate over the projection years and that treatment modalities do not 
change considerably over this period.  
Both dialysis- and transplant-treated-ESKD prevalence counts are predicted to increase 
steadily over the projection period. The number of patients treated with dialysis is predicted 
to increase by 49% from 10,988 in 2011 to 16,382 in 2020, while the number of patients with a 
functioning kidney transplant is predicted to increase by 73%, from 8,782 in 2011 to 15,227 in 
2020 (Figure 3.2).  
While the number of patients with a functioning kidney transplant is predicted to increase 
faster than for those receiving dialysis, in 2020 dialysis patients are still likely to account for a 
higher proportion of treated-ESKD patients: 52% of treated-ESKD cases are predicted to 
receive dialysis treatment for their ESKD in 2020 with the remaining 48% predicted to have a 
functioning kidney transplant. In 2011, the corresponding proportions were 56% and 44%, 
respectively. This is consistent with prevalence data from 2007 to 2011, which show an 
increase in the proportion of treated-ESKD patients with a functioning kidney transplant, 
from 42% to 44%, respectively.  
 
Notes 
1. The solid lines represent existing registry data while the dotted lines are for projected prevalent cases. 
2. The percentage increases from 2011 to 2020 for dialysis- and transplant-treated-ESKD cases are listed in the legend. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure 3.2: Prevalence of registered and projected treated-ESKD, by treatment type, 2003–2020 
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Influence of diabetes 
Over the last decade the prevalence of self-reported diabetes in Australia has more than 
doubled, increasing from 1.5% to 4.2% between 1989–90 and 2011–12 (AIHW 2013). This 
increasing prevalence of diabetes is a major contributor to the increase in CKD and treated-
ESKD in Australia, with diabetes now the leading primary cause of new cases of treated-
ESKD (ANZDATA 2013). In 2011, diabetes was the underlying cause in one-in-three new 
cases of treated-ESKD in Australia, compared with 13% in 1991 (ANZDATA 2013).  
To assess the influence of diabetes on future treated-ESKD prevalence counts, the same 
methodology as for the ‘base’ model was used to create separate models for treated-ESKD 
with and without a primary cause of diabetes. It is important to note that the projected sum 
of non-diabetes and diabetes-related treated-ESKD prevalent cases does not equal the ‘base’ 
model-derived results. This is because of differences in the historical trends for treated-ESKD 
patients with and without diabetes as a primary cause, and different transition probabilities 
used in the ‘base’ model. 
As shown in Figure 3.3, the prevalence of treated-ESKD is projected to increase faster for 
cases with diabetes listed as the primary cause than for patients without diabetes. The 
prevalence of treated-ESKD with diabetes as the primary cause is projected to more than 
double between 2011 and 2020 (from 4,392 in 2011 to 9,677 in 2020). This compares to a 47% 
projected increase (from 15,388 to 22,960 cases over this period) when diabetes is not the 
primary cause.  
The proportion of prevalent treated-ESKD cases with an underlying cause of diabetes is also 
projected to increase over this period. In 1996, 10% of prevalent cases had diabetes as the 
primary cause; this increased to 22% in 2011 and is projected to increase to 30% in 2020. 
These projection results indicate that the increasing burden of diabetes in Australia will 
continue to make a significant contribution to the increase in prevalence of treated-ESKD 
over the next decade. 
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Notes 
1. The solid lines represent existing registry data while the dotted lines are for projected prevalent cases. 
2. The projected sum of non-diabetes and diabetes-related treated-ESKD prevalent cases does not equal the ‘base’ model sum (see page 14). 
3. The percentage increase from 2011 to 2020 for both models is listed in the legend. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure 3.3: Prevalence of registered and projected treated-ESKD, by primary cause of treated-ESKD 
(diabetes versus non-diabetes), 2003–2020 
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4 Alternative models 
This chapter compares results from alternative models to those from the ‘base’ model. These 
alternative models were created based on the results of model-fit analyses that assessed the 
incidence and Markov-model components of the ‘base’ prevalence projections model (see 
Appendix C). The aim of presenting results from these models is to provide a range of 
projection results, based on altering select assumptions underpinning the ‘base’ projections 
model. 
Two alternative models to the ‘base’ model were constructed: a more conservative ‘stable 
incidence’ model and a less conservative ‘improving dialysis treatment outcomes’ model. 
Further information on the construction of these models is discussed in the Methods chapter 
and Appendix D. 
‘Stable incidence’ model 
Model-fit analysis comparing incidence projection data for the incidence model base years to 
the existing incidence data from the ANZDATA Registry (1996 to 2011) suggests that the 
‘base’ prevalence projections model may overestimate the incidence of treated-ESKD 
(Figure C1). The main source of this potential overestimation is incidence data from older 
age groups (ages 65–74 and 75-and-above) in the projections model (see Figures C5 and C6). 
The ‘stable incidence’ model acts as a ‘conservative estimate’ model by assuming that the 
2008–2011 (‘stable’) trend in incidence rates remains constant over the projection period. 
Other aspects of the model were the same as for the ‘base’ model. 
According to the ‘stable incidence’ model, the prevalence of treated-ESKD is projected to 
increase by 45% from 19,780 in 2011 to 28,756 in 2020 (compared to a predicted 60% increase 
to 31,589 cases in 2020 in the ‘base’ prevalence projections model) (Figure 4.1). 
The greatest relative difference between ‘base’ model and ‘stable incidence’ model results 
occurred in the 75-and-above incident age group (Table E4). In this age group, the ‘stable 
incidence’ model predicted 37% growth in prevalence of treated-ESKD from 2011 to 2020 
(with 2,499 cases in 2020), compared to 112% growth in the ‘base’ model (with 4,130 cases in 
2020).  
This analysis has shown that when incidence rates are held constant across the projection 
years (a conservative estimate of future incident counts), the prevalence of treated-ESKD still 
increases substantially. These results suggest that increasing incidence rates are not the only 
factor driving future growth in treated-ESKD prevalence.  
‘Improving dialysis treatment outcomes’ model 
Model-fit analyses of the Markov model component of the prevalence projections model (see 
Appendix C) appear to indicate that the ‘base’ model may underestimate the prevalence of 
treated-ESKD in older incident age patients (age groups 65–74 and 75-and-above) (Figure 
C7). This is most likely due to the model not controlling for improving dialysis treatment 
outcomes for older patients (age groups 65–74 and 75-and-above) over the projection years. 
The ‘improving dialysis treatment outcomes’ model attempts to factor in improving dialysis 
treatment outcomes for older patients by altering the dialysis-death and dialysis-dialysis 
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transition probabilities for older patients (age groups 65–74 and 75-and-above) over the 
projection years. Other aspects of the model were the same as for the ‘base’ model. 
According to the ‘improving dialysis treatment outcomes’ model, the prevalence of treated-
ESKD is projected to increase by 64% from 19,780 cases in 2011 to 32,437 in 2020. This 
compares to a predicted 60% increase to 31,589 cases in 2020 in the ‘base’ prevalence 
projections model (Figure 4.1). 
In the 65–74 incidence age group, the ‘improving dialysis treatment outcomes’ model 
predicted a 83% growth in the prevalence of treated-ESKD from 2011 to 2020 (with 5,179 
cases in 2020), compared with a 72% increase in the ‘base’ model (to 4,858 cases in 2020).  
In the 75-and-above incident age group, the ‘improving dialysis treatment outcomes’ model 
predicted 155% growth in the prevalence of treated-ESKD from 2011 to 2020 (with 4,658 
cases in 2020), compared with a 112% increase in the ‘base’ model (with 4,130 cases in 2020) 
(see Table E4). 
This analysis has shown that when potential improvements in dialysis survival are factored 
into the projections model, the prevalence of treated-ESKD still increases at a similar rate to 
that in the ‘base’ model.  
 
Notes  
1. The solid lines represent existing registry data while the dotted lines are for projected prevalent cases. 
2. The percentage increases from 2011 to 2020 for the models are listed in the legend. 
3. Detailed projection results for all models are presented in Table E3 and by incident age group in Table E4. 
The solid line represents existing registry data while the dotted lines are for projected prevalent cases. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure 4.1: Comparison of treated-ESKD prevalence projection results using the various models, 
2003–2020 
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5 Discussion 
This report has highlighted that the prevalence of treated-ESKD is predicted to increase 
rapidly and considerably over the next decade. In 2011, there were just under 20,000 cases of 
treated-ESKD in Australia, with all three models—’base’, ‘stable incidence’ and ‘improving 
dialysis treatment outcomes’—predicting that this number is projected to increase to between 
29,000 and 32,000 by 2020. All models predict at least a 45% growth in the prevalence of 
treated-ESKD between 2011 and 2020, with the ‘base’ and ‘improving dialysis treatment 
outcomes’ models predicting a growth in treated-ESKD prevalence of at least 60%. This is 
despite the Australian population only increasing 13% over this period (ABS 2013a). 
The increasing prevalence predicted by the ‘stable incidence’ model (45% growth), and the 
relatively small (13%) population increase predicted over the projection years, suggest that 
there are other factors driving the predicted increase in the prevalence of treated-ESKD. 
Other likely contributing factors for future prevalence growth include: the ageing 
population; changes in propensity to treat ESKD with KRT; and improvements in survival 
for KRT patients. While it would be useful to detail the exact contribution of these factors on 
future prevalence growth, the projections methodology used in this report does not allow for 
such analysis. Some of these factors, such as propensity to treat, are also not able to be 
predicted.  
Dialysis- and transplant-treated-ESKD prevalence counts are both predicted to increase 
steadily over the projection period. The number of patients treated with dialysis is predicted 
to increase 49% from 10,988 in 2011 to 16,382 in 2020, while the number of patients with a 
functioning kidney transplant is predicted to increase by 73%, from 8,782 in 2011 to 15,227 in 
2020. The proportion of treated-ESKD patients with a functioning kidney transplant is 
estimated to increase to 48% in 2020 (compared with 44% in 2011).  
Diabetes-specific projection results also suggest that the burden of diabetes-related treated-
ESKD will continue to influence the increase in the prevalence of treated-ESKD over the next 
decade. The prevalence of treated-ESKD cases with diabetes as the primary cause is 
projected to increase 109% between 2011 and 2020, compared to a 47% increase for cases 
where diabetes is not the primary cause.  
The projection results presented in this report are based on the projection assumptions 
outlined in Chapter 2, including the assumption that recent (2009 to 2011) KRT treatment 
patterns will continue over the projection years. 
Implications of projections 
The projected increase in the prevalence of treated-ESKD has significant implications for 
health service planning and resource allocation in the future, including the probable 
increasing need for dialysis services and kidney transplants. However, these results also 
highlight the ongoing need to prevent CKD and the progression of CKD to ESKD, by 
eliminating or reducing modifiable risk factors such as high blood pressure, tobacco smoking 
and obesity. The projection results also suggest that diabetes will continue to be a major 
driver of increases in treated-ESKD prevalence, and will continue to be an important area for 
further prevention activities. Such activity could include increased and early CKD screening 
in people with diabetes and other at-risk groups, as many interventions to slow progressive 
CKD are more successful the earlier they are initiated (Thomas 2007).  
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The issue of untreated-ESKD 
The projection estimates presented in this report are based on data for patients already 
receiving KRT for their ESKD, and do not include those that are not receiving KRT. Previous 
AIHW analysis has shown that in 2003–2007, for every new ESKD patient who received KRT, 
there was one who did not (AIHW 2011b). The vast majority (more than 80%) of the new 
ESKD patients who did not receive KRT were aged over 70 years. The reasons for some 
patients not receiving KRT are not fully understood: prognosis; anticipated quality of life 
(with or without KRT); treatment burden on the patient; and patient preference all play a 
part in the decision for or against KRT (Murtagh et al. 2007). As a considerable number of 
new ESKD patients are not receiving KRT, this is also likely to be the case for prevalent 
treated-ESKD cases. This suggests that the treated-ESKD prevalence estimates presented in 
this report may be an underestimate of the true prevalence of future ESKD cases. 
If the propensity for people to receive KRT changes over the projection years, it is possible 
that there could be a greater increase in the incidence of treated-ESKD and an increase in the 
number of people starting KRT treatment for their ESKD. This increase would likely lead to 
higher prevalence estimates than those presented in this report.  
Future projections work 
The prevalence projections models presented in this report provide a useful foundation for 
further testing the influence of certain drivers for the likely future increase in the prevalence 
of treated-ESKD. Such work is essential for better targeting of ESKD prevention strategies. 
For example, the model could be altered to assess the impact of further diabetes scenarios, 
such as the impact of possible reductions in new diabetes-related treated-ESKD cases. 
The ‘base’ prevalence projections model could also be further altered to assess the impact of 
future changes in KRT treatment patterns on treated-ESKD prevalence and survival. For 
example, the effect of increasing kidney transplant rates to levels seen in other countries 
could be assessed, as well as the extent of any possible gains, in terms of increased survival, 
for such a scenario. Recent projections work undertaken for Kidney Health Australia 
indicates that increasing the rate of kidney transplantation by 50%, to match rates currently 
achieved in the United States and numerous European countries, would be associated with 
cost savings and greater health benefits (Cass et al. 2010). 
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Appendix A: Treatment options for end-
stage kidney disease (ESKD) 
Kidney replacement therapy (KRT) 
KRT refers to procedures which temporarily or permanently remedy insufficient cleansing of 
body fluids by the kidneys. There are two forms of KRT: dialysis and kidney transplantation.  
Dialysis 
Dialysis is an artificial method of removing waste substances from the blood and regulating 
levels of circulating chemicals – functions normally performed by the kidneys. There are two 
main types of dialysis: peritoneal and haemodialysis.  
Which form is used depends on the patient’s health, age and lifestyle, and is influenced by 
the availability of local resources. 
Haemodialysis is a form of dialysis where a machine is connected to a person’s bloodstream 
to filter the blood externally to the body. This type of dialysis can be done at home, in 
hospital, or in satellite dialysis units. The main advantage of haemodialysis is that it 
generally takes a shorter amount of time and is done on fewer days each week than 
peritoneal dialysis. Its limitations are that patients need to plan their activities around their 
dialysis sessions; the need for special equipment limits a patient’s ability to travel; and a 
patient’s diet and the amount of fluid they can consume are limited (NHS 2013). 
Peritoneal dialysis is a form of dialysis where a solution is pumped into the abdominal 
cavity where the body’s own peritoneum membrane acts as a dialysis filter to remove waste 
products and water. Peritoneal dialysis can either be performed by the patient during the 
day (continuous ambulatory dialysis), usually 3 or 4 times a day, or automatically by a 
machine at night for around 8–10 hours while patient sleeps (automated peritoneal dialysis). 
The advantages of peritoneal dialysis include not having to make regular visits to a dialysis 
centre or have bulky equipment installed in the home; greater capacity for travel as the 
equipment required for peritoneal dialysis is portable; and fewer restrictions on diet and 
fluid intake. The limitations on peritoneal dialysis include that it needs to be carried out 
every day, and it increases the risk of developing inflammation of the abdominal lining 
(peritonitis) (NHS 2013). 
Kidney transplantation 
Transplantation is considered the preferred option for KRT by patients and health-care 
professionals (Mathew et al. 2005). Advantages of transplantation over dialysis include 
increased life expectancy and quality of life, and lower costs (Karnellis 2008). Drawbacks 
include taking ongoing medications to prevent rejection of the kidney, as these medications 
may cause complications (CIHI 2013). Donated kidneys come from either deceased or living 
donors (Kidney Health Australia 2007).  
A number of factors can prevent people from being considered for kidney transplantation, 
including age; other health conditions; lifestyle factors such as obesity; smoking, drug and 
alcohol abuse; and an inability to comply with complex medical therapy (TSANZ 2011).  
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Transplantation can occur without a patient starting dialysis first, and in 2011 11% of all 
transplants in Australia were for patients receiving their first transplant without prior 
dialysis treatment (pre-emptive transplants) (ANZDATA 2013). This has advantages as the 
length of time spent on dialysis before transplantation is related to increased risk of mortality 
and decreased survival rates of the donated kidney (Karnellis 2008). 
Transplants from living donors are considered to have several advantages over deceased-
donor kidneys. These include avoidance of lengthy dependence on dialysis while waiting for 
a transplanted kidney from a deceased donor; the possibility of receiving a better matched 
kidney from a relative; the period that the kidney is without blood supply and ‘on ice’ is 
shorter, which means that the transplanted kidney usually works immediately; the 
transplant can be scheduled at a time suitable for the donor, the recipient and the transplant 
team; and live-donor kidneys work better and last longer than kidney transplants from 
deceased donors (Renal Resource Centre 2010). In 2011, 31% of kidney transplants came from 
living donors (ANZDATA 2013). 
Non-KRT treated-ESKD 
Non-KRT medical management of ESKD is another treatment choice and involves a shift 
from efforts to prolong life to focusing on care, quality of life and symptom control (Chandna 
et al. 2011). Prognosis; anticipated quality of life (with or without dialysis); treatment burden 
(if dialysis is undertaken); and patient preferences all play a part in the decision for or 
against KRT (Murtagh et al. 2007). Medications, diet and other therapies may be used to 
lessen symptoms. It is generally older patients that do not receive KRT to treat their ESKD 
(AIHW 2011a), due to factors such as comorbidities, length of lifespan, and quality of life 
(Murtagh et al. 2007). 
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Appendix B – Statistical methods  
Time-series analysis 
Time-series analyses presented throughout this report have used linear regression analysis to 
determine whether there have been significant increases or decreases in the observed rates 
for the period. In this report, comments have been made on significant increases or decreases 
only.  
Percentage increases over the projection years were calculated using the last available 
registry data point (2011) as a base year. Using linear regression analysis means that all 
points within the analysis period are factored in when calculating total percentage changes, 
therefore limiting the influence of potential outliers. 
Time-series data in this report are generally presented for the 18-year period from 2003 to 
2020. The first 9 years of the period (2003 to 2011) consist of existing ANZDATA registry 
data while the remaining 9 years are projection results (2012 to 2020). 
Prevalence model construction 
The construction of the prevalence model involved two stages: projection of the incidence of 
dialysis- and transplant-treated-ESKD cases, and follow-up of these projected incident cases 
and existing prevalent cases to 2020. 
Estimating the incidence of dialysis-treated- and 
transplant-treated-ESKD 
Incident dialysis- and transplant-treated-ESKD counts needed to be projected for each year 
of the 2012 to 2020 projection period, as these were inputs into the projection model. 
The first step in projecting the number of new transplant and dialysis cases required 
projecting the overall incidence of treated-ESKD. Incident transplant and dialysis cases were 
then estimated based on these numbers. 
Projecting the incidence of treated-ESKD 
The incidence of treated-ESKD was projected using the log-linear Poisson regression 
technique that was previously used by the AIHW for projecting the incidence of treated-
ESKD (AIHW 2011b).  
Projection of the incidence of treated-ESKD involved firstly summarising historical trends in 
the incidence rates reported by the ANZDATA Registry; identifying the most recent trend by 
examining existing data and using Joinpoint regression; and extrapolating it into the future 
(AIHW 2011b). The second step is the projection of incidence rates using the latest ABS 
population series B population projections (ABS 2013a).  
Like other projections of disease incidence, the most important assumption in this report is 
that the most recent historical trend will continue into the future. An age-period modelling 
approach, which assumes disease incidence is a function of age (in age group) and period (in 
calendar year) effects, was applied to describe and extrapolate the historical trends of the 
incidence of treated-ESKD. The advantage of this approach is that the age and period effects 
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are treated as a proxy for the underlying causes of the disease’s incidence (Dyba et al. 1997), 
involving minimal subjective judgement. The incidence model was also stratified by sex. 
The age-period model used in this analysis is a log-linear Poisson regression mode (Kuh & 
Ben-Shlomo 2004). This model assumes the incidence of treated-ESKD, as a rare disease, 
followed a Poisson distribution. The model also assumes that the logarithmic transformed 
incident cases (with the population as an offset) is a function of age and period effects. The 
extrapolated incidence rates display an exponential growth trend.  
The incidence model in this report used 5 age groupings (0–29, 30–49, 50–64, 65–74 and 75-
and-above) and had 2 years of base data additional to those previously published AIHW 
projections work (1996 to 2011, instead of 1996 to 2009) (AIHW 2011b). 
Projected incident treated-ESKD cases for each age group were estimated by applying 
projected incidence rates to the latest ABS population series B population projections (ABS 
2013a). 
Estimating dialysis and transplant counts 
It is rare to start KRT with kidney transplantation (pre-emptive transplant); particularly in 
older age groups. This made it unsuitable to project pre-emptive transplant counts using a 
similar log-linear Poisson regression to the one used to project overall incident treated-ESKD 
cases. The projected numbers of pre-emptive transplants in each age group model were 
estimated using the latest trends in pre-emptive transplant rates. These counts were 
estimated by applying the average proportion of incident cases in 2008 to 2011 that were first 
treated with a (pre-emptive) transplant to the overall projected treated-ESKD incident count 
for each projection year. For example, for each year in the 0–29 incident age model, the 
estimated number of transplants was 21% of all projected incident cases for that age group.  
The number of incident dialysis cases for each projection year was estimated as the number 
of remaining cases after applying the transplant proportion. For example, the estimated 
number of incident dialysis cases for each year of the 0–29 incident age model was 79% of the 
projected total treated-ESKD count each year.  
Over the last decade there has been a slight increase in the proportion of younger (0–29,  
30–49 and 50–64) incident treated-ESKD cases that received a pre-emptive transplant. This 
potentially means that the method used to estimate pre-emptive transplants may lead to an 
overall underestimation in the projected prevalence of treated-ESKD for younger age groups 
(as transplant patients tend to have better survival compared to dialysis cases).  
Follow-up of projected incident cases and existing 
prevalent patients 
Existing prevalent patients and projected incident patients were followed through the 
projection years using the ‘base’ prevalence projections model, consisting of 5 separate 
Markov models. These Markov models differed based on the incident age of the patients 
feeding into them (age groups 0–29, 30–49, 50–64, 65–74 and 75-and-above). 
The ‘base’ model was based on incident age, rather than current age, as the projections 
methodology used did not allow for patients to move between the 5 Markov models as they 
aged during the projection period.  
 24 Projections of the prevalence of treated end-stage kidney disease in Australia 
Markov models 
Markov models are capable of modelling clinical conditions when risk is continuous over 
time. Markov models assume that a patient is always in one of a finite number of states 
referred to as Markov states. All events of interest are modelled as transitions from one state 
to another (Sonnenberg & Beck 1993); for example, from dialysis to death or from transplant 
to dialysis. 
The Markov models used in the base prevalence model were divided into equal increments 
of time called Markov cycles. During each cycle, a patient may transition from one state to 
another or remain in the same state. It is assumed that a patient in a given state can only 
make a single state transition during a cycle (see ‘Projection Assumptions’ in Chapter 2). 
Often the choice of a cycle time will be determined by the available probability data, but a  
1-year cycle is generally appropriate for relatively rare events, such as ESKD (Sonnenberg & 
Beck 1993). ANZDATA Registry records are also provided on a yearly basis, meaning that a 
1-year cycle is the shortest cycle possible.  
The prevalence of treated-ESKD was projected from 2012 to 2020, using a series of 5 Markov 
models. These models incorporated transfers between dialysis, transplant and death: that is, 
3 Markov states (see Figure B1). There are 6 possible transitions between these states: dialysis 
to death; transplant to death; transplant to dialysis; dialysis to transplant; remaining on 
dialysis; or remaining with a functioning transplant. 
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Notes 
1. The dotted lines represent the possible transitions within a Markov cycle. 
2. Solid lines represent the outputs for the cycle after the cycle period (1 year) ends. These cases were inputs into the next projection year’s 
 cycle (see Figure B2). 
3. Only one transition can occur during each Markov cycle (1 year). 
Figure B1: Markov states and possible transitions during a Markov cycle (1 year) in the five 
Markov models making up the ‘base’ treated-ESKD prevalence projections model  
Controlling for the effect of treatment length and incident age on Markov-state 
transition probabilities 
The probabilities associated with transitioning between the 3 Markov states (transition 
probabilities) in Figure B1 depend on a number of factors, including patient age and the 
duration of their KRT treatment. Other factors, such as comorbid conditions, KRT treatment 
history and ethnicity also influence transition probabilities but these were not controlled for 
in the model (see Methods chapter). 
Age-related differences in treatment outcomes (transition probabilities) were controlled for 
in the ‘base’ projections model by having different transition probabilities in the 5 incident 
age group Markov models used in the ‘base’ model (see Table B1).  
The influence of treatment length was controlled for within each of the 5 Markov models by 
having 5 parallel Markov cycles (see Figure B2) in each projection year for patients of 
differing KRT treatment duration. The 5 Markov cycles included in each year of each Markov 
model were for patients during their: 
• incident year, that is, first year of treatment (1 year) 
• second year of treatment year (2 year) 
• third year of treatment (3 year)  
• fourth year of treatment (4 year)  
• fifth or subsequent year of treatment (5 year).  
Within each age group Markov model, each of these treatment-length Markov cycles had 
different transition probabilities, although these probabilities remained constant over the 
projection years. For example, the probability of transitioning from dialysis to transplant 
during the second year of treatment in the 50–64 incident age model was the same in every 
projection year. 
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Controlling for age and treatment length in the projections model resulted in 25 Markov 
cycles occurring in each projection year – 5 treatment-length cycles x 5 incident-age models.  
Calculating transition probabilities 
Transition probabilities for the 5 different Markov cycles in each incident age group model 
were based on the latest trends in treatment outcomes for treated-ESKD patients. The latest 
treatment trends were assessed by calculating the average transition probabilities for 
prevalent ANZDATA-registered patients during 2009–2011. Three years’ worth of transition 
data were required due to small cell sizes for some of the transitions.  
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Table B1: Transition probabilities used to follow up existing prevalent patients and projected 
incident patients in the projection of the prevalence of treated-ESKD 
Transition Treatment length 
Transition probabilities by incident age group 
0–29 30–49 50–64 65–74 75+ 
Dialysis – Dialysis 1 year 0.855 0.914 0.926 0.904 0.876 
Dialysis – Transplant 1 year 0.104 0.054 0.024 0.005 0.000 
Dialysis – Death 1 year 0.041 0.032 0.050 0.092 0.124 
Transplant – Dialysis 1 year 0.016 0.013 0.006 0.000 0.000 
Transplant – Transplant 1 year 0.984 0.974 0.977 0.963 0.000 
Transplant – Death 1 year 0.000 0.013 0.018 0.037 0.000 
Dialysis – Dialysis 2 years 0.652 0.806 0.828 0.860 0.805 
Dialysis – Transplant 2 years 0.311 0.124 0.072 0.013 0.000 
Dialysis – Death 2 years 0.038 0.070 0.100 0.127 0.195 
Transplant – Dialysis 2 years 0.017 0.000 0.006 0.000 0.000 
Transplant – Transplant 2 years 0.949 1.000 0.970 1.000 0.000 
Transplant – Death 2 years 0.034 0.000 0.024 0.000 0.000 
Dialysis – Dialysis 3 years 0.735 0.826 0.817 0.828 0.780 
Dialysis – Transplant 3 years 0.242 0.116 0.085 0.020 0.000 
Dialysis – Death 3 years 0.024 0.057 0.098 0.152 0.220 
Transplant – Dialysis 3 years 0.033 0.012 0.000 0.000 0.000 
Transplant – Transplant 3 years 0.962 0.982 0.974 1.000 0.000 
Transplant – Death 3 years 0.005 0.006 0.026 0.000 0.000 
Dialysis – Dialysis 4 years 0.792 0.822 0.829 0.829 0.786 
Dialysis – Transplant 4 years 0.188 0.113 0.072 0.015 0.001 
Dialysis – Death 4 years 0.021 0.064 0.098 0.156 0.213 
Transplant – Dialysis 4 years 0.028 0.002 0.003 0.017 0.000 
Transplant – Transplant 4 years 0.967 0.989 0.978 0.950 0.000 
Transplant – Death 4 years 0.005 0.009 0.020 0.033 0.000 
Dialysis – Dialysis 5 years and above 0.849 0.822 0.812 0.816 0.761 
Dialysis – Transplant 5 years and above 0.134 0.109 0.076 0.014 0.000 
Dialysis – Death 5 years and above 0.017 0.069 0.112 0.170 0.239 
Transplant – Dialysis 5 years and above 0.023 0.004 0.008 0.017 0.000 
Transplant – Transplant 5 years and above 0.972 0.989 0.977 0.948 0.000 
Transplant – Death 5 years and above 0.005 0.008 0.015 0.034 0.000 
Notes 
1. The above transition probabilities were used in the construction of 5 Markov models in the ‘base’ model and ‘stable incidence’ model – see 
Prevalence model construction (Appendix B). 
2. Transition probabilities were calculated by following a cohort of treated-ESKD patients during 2009–2011. 
3. Five-year transition probabilities were used for treated patients who had received treatment for 5 years or longer. 
4. The prevalence model assumed that only a patient’s current treatment modality, incident age and treatment length influenced transition 
probabilities.  
Source: AIHW analysis of ANZDATA Registry data. 
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Inputs for Markov models 
For all projection years, in each incident age group model, estimated incident dialysis- and 
transplant-treated patients acted as the inputs for the 1-year cycles (see arrows entering the  
1-year cycle in Figure B2).  
In the first projection year, existing 2011 prevalent patients who started treatment at the 
same age as the incident patients feeding into the year 1 cycle (that is, had the same incident 
age) were the inputs for the 2-, 3- and 4-year and 5-years-and-above cycles (see 2012 cycle in 
Figure B2). During each projection year, patients could undergo one of 6 possible transitions 
(see dotted lines). If patients died during a projection year they dropped out of the model, 
while the surviving patients acted as inputs for the 2-, 3- and 4-year and the 5-years-and-
above cycles of the subsequent year (see inputs into these cycles in 2013 in Figure B2). For 
example, the dialysis and transplant patients remaining at the end of the 2 year cycle in 2011 
acted as inputs for 3 year cycle in 2012. 
Patients remained in the same Markov model throughout the entire projection period, as 
each model was based on incident age, not current age. Current age could not be factored 
into the model as Markov modelling techniques are cohort-based. 
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Notes 
1. The ‘base’ prevalence model had 5 separate parallel Markov models, with the same structure as above, for patients of differing incident 
ages (age groups 0–29, 30–49, 50–64, 65–74 and 75-and-above). 
2. The 5 Markov cycles within each Markov cycle for each projection year were for patients of differing treatment length. Each cycle had three 
possible states (D – Dialysis, T – Transplant, X – Death), resulting in six possible transitions during each cycle (D-D, D-T, D-X, T-T, T-D and 
T-X). 
3. The dotted lines represent the possible transitions within each Markov cycle. 
4. Solid lines represent the outputs for the cycle after the cycle period.  
5. Existing prevalent patients in the same incident age group acted as inputs for the 2–5+ year cycles in 2012. 
6. The inputs and output pattern of the model from 2013 onwards remained the same; that is, incidence data acted as the input for the 1 year 
model and the outputs from the previous year’s model acted as the input for the other cycles. 
7. See Table B1 for the transition probabilities used in each Markov model. 
Figure B2: Markov model component used in projection of the prevalence of treated-ESKD 
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Appendix C – Model accuracy 
Appendix C aims to independently assess the accuracy of the two components of the ‘base’ 
prevalence projections model: the incidence component and the follow-up component. 
Incidence model accuracy 
The analysis below assesses the model-fit of the incidence model by fitting the incidence 
projection data for incidence model base years to the existing incidence data from the 
ANZDATA Registry (1996 to 2011). A similar approach was taken in previous AIHW 
treated-ESKD incidence projection work (AIHW 2011b).  
The overall incidence model fits existing incidence data well (see Figures C1–C6). However, 
the model appears to possibly overestimate the incidence of treated-ESKD in the 65–74 and 
75-and-above age groups (Figure C5 and C6). This is most likely to be due to flattening in the 
incidence of treated-ESKD over the last 3 to 4 years for all (incident) age groups used in the 
prevalence projection model (see Figures C.1–C6). These findings appear to suggest that 
recent historical trends (1996–2011) in the incidence of treated-ESKD may not continue in the 
prevalence projection years (2012–2020), which is one of the key assumptions underpinning 
the ‘base’ projections model (see Chapter 2: Methods). As a result of this analysis, a 
prevalence projections model was constructed based on the assumption that incidence rates 
will remain constant over the projection years (see Chapter 4 and Appendix D).  
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Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C1: Annual incident counts of registered and projected treated-ESKD patients, 1996−2011 
 
 
Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C2: Annual incident counts of registered and projected treated-ESKD patients, 0−29 age 
group, 1996−2011 
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Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C3: Annual incident counts of registered and projected treated-ESKD patients, 30−49 age 
group, 1996−2011 
 
 
Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C4: Annual incident counts of registered and projected treated-ESKD patients, 50−64 age 
group, 1996−2011 
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Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C5: Annual incident counts of registered and projected treated-ESKD patients, 65−74 age 
group, 1996−2011 
 
 
Note: The squares represent existing registry data while the dotted line is for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C6: Annual incident counts of registered and projected treated-ESKD patients, 75+ age 
group, 1996−2011 
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Follow-up of patients over the projection period 
This section assesses the accuracy of the Markov model-based method for following up 
existing prevalent patients and projected new patients (incident patients) over the projection 
period.  
Model accuracy was assessed by projecting the prevalence of treated-ESKD from 2003 to 
2011 (the same number of projection years as for the ‘base’ model), using the same overall 
methods for following up patients, as discussed in Appendix B. These results were then 
compared to existing ANZDATA Registry data from the same period to assess model-fit. 
Transition probabilities in the 2003 to 2011 model were calculated by following a cohort of 
patients who started KRT treatment in 2001 to 2003 (the same cohort length as the ‘base’ 
model). Actual incidence data were the inputs for the model, rather than projected patients, 
so accuracy of the Markov model methodology could be assessed separately to the projected 
incidence results feeding into this model. 
Similar incidence and follow-up model-fit analyses have been carried out in other Markov 
modelling work (Gilbertson et al. 2005; Schaubel et al. 1998), but not for Australian-based 
ESKD prevalence projections work. 
Generally, the prevalence of treated-ESKD was quite similar for registry data and projection 
data (Figure C7), with the Markov model component of the projections model slightly (2.0%) 
underestimating true prevalence counts. Only small differences occurred between registry 
data and projection data for most incident age groups; however, the models for age groups 
65–74 (8.1%) and 75-and-above (16.1%) underestimated true prevalence counts.   
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Note: The solid lines represent existing registry data while the dotted lines are for projected prevalent patients. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C7: Prevalence of registered and projected treated-ESKD, for all patients and by incident 
age, 2003–2011 
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These results suggest that the assumptions underpinning the ‘base’ model for following up 
existing prevalent patients lead to a underestimation in projection results in older incident 
age groups (ages 65–74 and 75-and-above), assuming similar treatment and incidence trends 
that occurred from 2003 to 2011 also occur from 2012 to 2020.  
For older patients, the assumption most likely to be disproven is that treatment outcomes 
(transition probabilities) remain constant over the projection years. In particular, over the last 
decade there has been an improvement in dialysis survival for older patients (that is, a 
decrease in dialysis-death transition probabilities). Figure C8 shows the change in dialysis-
death transition probabilities between the base years used to calculate the model-fit 
probabilities (1999–2001) and the base years used in the ‘base’ model (2009–2011). All 
transitions in the 75-and-above model, and all in the 65–74 age group model (except the 1 
year cycle) show an improvement in dialysis treatment outcomes over time (Figure C8).  
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Notes 
1. Time period refers to KRT treatment length for prevalent cohort. 
2. Probability refers to the likelihood of dying while on dialysis (Dialysis – Death transition). 
3.  Decreases in transition probabilities over time indicate improved dialysis survival. 
Source: AIHW analysis of ANZDATA Registry data. 
Figure C8: Dialysis survival (likelihood of dying while on dialysis) for patients during 2001–2003 
and 2009–2011, by treatment length and age. 
As a result of improving dialysis treatment outcomes in older incident dialysis patients, a 
prevalence-projections model was constructed based on the assumption that similar 
improvements in survival will occur over the prevalence projection years (see Chapter 4 and 
Appendix D). 
0
0.05
0.1
0.15
0.2
0.25
0.3
2001–2003 2009–2011 
1 year
2 years
3 years
4 years
5 years
Probability 
Transition Period 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
2001–2003 2009–2011 
1 year
2 years
3 years
4 years
5 years
Probability 
Transition period 
75+ age group 
65–74 age group 
 38 Projections of the prevalence of treated end-stage kidney disease in Australia 
Appendix D – Alternative models 
The model-accuracy analyses in Appendix C appear to indicate that the two following ‘base’ 
projection model assumptions might not hold over the projection years:  
• Assumption 1: Recent historical trends in the incidence of dialysis- and transplant 
treated-ESKD will continue in the projection years.  
• Assumption 2: Transition probabilities in each age group Markov model will remain 
constant over the projection years.  
As a result of these model-accuracy analyses, two alternative models were constructed and 
compared to the ‘base’ model results, to give a range of prevalence results based on different 
projection scenarios. These results are presented in Chapter 4. 
‘Stable incidence’ model 
The potential for overestimation of future incidence rates was addressed in the ‘stable 
incidence’ model, which acts as a ‘conservative estimate’ model. The model assumes that the 
2008–2011 (‘stable’) trend in incidence rates remains constant over the projection years. In 
this model, the average yearly incidence rate from 2008–2011, for each age group, was 
applied to the projection year populations to calculate estimated incident counts over the 
projection years. Incident dialysis and transplant patients were estimated from these 
(‘stable’) incidence counts using the same method as for the ‘base’ model (see Appendix B). 
All other aspects of the model remained the same as the ‘base’ projections model. 
‘Improving dialysis treatment outcomes’ model  
Model-fit analyses of the Markov model component of the prevalence-projections model (see 
Appendix C) appear to indicate that the ‘base’ model may underestimate the prevalence of 
treated-ESKD in older incident age patients (age groups 65–74 and 75-and-above) (Figure 
C7). This is most likely to be due to the model not controlling for improving dialysis 
treatment outcomes for older patients (age groups 65–74 and 75-and-above) over the 
projection years. 
The ‘improving dialysis treatment outcomes’ model attempted to factor in improving 
dialysis treatment outcomes for older patients by altering the dialysis-death and dialysis-
dialysis transition probabilities for older patients (age groups 65–74 and 75-and-above) over 
the projection years. The first step in the process was to use linear regression to calculate the 
annual rate (%) of change in dialysis-deaths transition probabilities over the 8 years (2003–
2011) preceding the 8-year projection period (2012–2020) for the 5 treatment-length groups in 
the 2 older incident-age groups. This analysis resulted in 10 annual rates of change figures (5 
for each incident age group).  
The relevant annual-rate-of-change value was then applied over the projection years to the 
dialysis-death transitions, and the difference in probability as a result of this was added to 
the dialysis-dialysis (that is, dialysis survival) transitions. Any improvements in survival (in 
terms of reduction in dialysis-death transition probability) were applied to the dialysis-
dialysis transitions, rather than to the dialysis-transplant transition probabilities, because the 
likelihood of transplantation is low in the 65–74 and 75-and-above incident age groups. (See 
Table D1 for a full list of the revised dialysis-dialysis and dialysis-death transitions 
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probabilities used in the ‘improving dialysis treatment outcomes’ model.) All other aspects 
of the ‘improving dialysis treatment outcomes’ model were the same as for the ‘base’ model. 
Table D1: Transition probabilities used to follow-up existing prevalent patients and projected 
incident patients in the ‘improving dialysis treatment outcomes’ model 
Treatment length Projection year 
Transition probabilities by incident age group and transition 
65–74 age group 75+ age group 
Dialysis–Dialysis Dialysis–Death Dialysis–Dialysis Dialysis–Death 
1 year 2012 0.899 0.095 0.878 0.122 
1 year 2013 0.894 0.100 0.878 0.122 
1 year 2014 0.889 0.105 0.879 0.121 
1 year 2015 0.884 0.110 0.879 0.121 
1 year 2016 0.878 0.116 0.879 0.121 
1 year 2017 0.872 0.122 0.879 0.121 
1 year 2018 0.866 0.128 0.879 0.121 
1 year 2019 0.860 0.134 0.879 0.121 
1 year 2020 0.853 0.141 0.879 0.121 
2 years 2012 0.863 0.123 0.808 0.192 
2 years 2013 0.867 0.119 0.811 0.189 
2 years 2014 0.871 0.116 0.815 0.185 
2 years 2015 0.875 0.112 0.818 0.182 
2 years 2016 0.878 0.109 0.821 0.179 
2 years 2017 0.881 0.105 0.824 0.176 
2 years 2018 0.885 0.102 0.827 0.173 
2 years 2019 0.888 0.099 0.830 0.170 
2 years 2020 0.891 0.096 0.833 0.167 
3 years 2012 0.831 0.149 0.787 0.213 
3 years 2013 0.834 0.146 0.793 0.207 
3 years 2014 0.838 0.142 0.799 0.201 
3 years 2015 0.843 0.137 0.805 0.195 
3 years 2016 0.847 0.133 0.811 0.189 
3 years 2017 0.851 0.129 0.816 0.184 
3 years 2018 0.855 0.125 0.822 0.178 
3 years 2019 0.859 0.121 0.827 0.173 
3 years 2020 0.863 0.117 0.832 0.168 
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Table D1 (continued): Transition probabilities used to follow-up existing prevalent patients and 
projected incident patients in the ‘improving dialysis treatment outcomes’ model 
 
Treatment length Projection year 
Transition probabilities by incident age group and transition 
65–74 age group 75+ age group 
Dialysis–Dialysis Dialysis–Death Dialysis–Dialysis Dialysis–Death 
4 years 2012 0.834 0.152 0.795 0.204 
4 years 2013 0.838 0.148 0.803 0.195 
4 years 2014 0.841 0.144 0.812 0.187 
4 years 2015 0.845 0.140 0.819 0.179 
4 years 2016 0.849 0.136 0.827 0.172 
4 years 2017 0.853 0.133 0.834 0.165 
4 years 2018 0.856 0.129 0.841 0.158 
4 years 2019 0.860 0.126 0.848 0.151 
4 years 2020 0.863 0.123 0.854 0.145 
5 years and above 2012 0.821 0.165 0.768 0.232 
5 years and above 2013 0.826 0.161 0.774 0.226 
5 years and above 2014 0.830 0.156 0.781 0.219 
5 years and above 2015 0.834 0.152 0.788 0.212 
5 years and above 2016 0.839 0.148 0.794 0.206 
5 years and above 2017 0.843 0.144 0.800 0.200 
5 years and above 2018 0.847 0.140 0.806 0.194 
5 years and above 2019 0.851 0.136 0.812 0.188 
5 years and above 2019 0.854 0.132 0.817 0.183 
Notes 
1. The transition probabilities in this table were used in the construction of the 65–74 and 75+ Markov models in the ‘improving dialysis 
treatment outcomes’ model. 
2. Transplant transition probabilities (transplant-death, transplant-transplant, dialysis-transplant) and transition probabilities in the ages 0–29, 
30–49, 50–64 models were the same as for the ‘base’ model. 
Source: AIHW analysis of ANZDATA Registry data. 
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Appendix E – Detailed data 
Existing treated-ESKD incidence trends 
Figure E1 below illustrates the recent stabilising of the incidence of treated-ESKD. The ‘stable 
incidence’ model controls for this trend and is explained in the ‘stable incidence’ model 
section of the Methods chapter. 
 
Source: AIHW analysis of ANZDATA Registry data. 
Figure E1: New treated-ESKD patients, by incident age, 1996 to 2011 
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Incidence projection results  
Table E1: Projected dialysis-treated and transplant-treated incident ESKD counts from the ‘base’ 
model, 2012–2020 
Year Incident dialysis patients Incident transplant patients Total incident patients 
2012 2,699 111 2,810 
2013 2,826 114 2,940 
2014 2,960 117 3,077 
2015 3,099 119 3,218 
2016 3,243 122 3,365 
2017 3,398 125 3,523 
2018 3,562 128 3,690 
2019 3,737 131 3,868 
2020 3,928 134 4,062 
Source: AIHW analysis of ANZDATA Registry data. 
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Table E2: Projected dialysis-treated and transplant-treated incident ESKD counts  
from the ‘base’ model, by age group, 2012–2020 
Year Age group Incident dialysis patients Incident transplant patients Total incident patients 
2012 0–29 109 22 131 
2013 0–29 109 22 131 
2014 0–29 109 23 132 
2015 0–29 110 23 133 
2016 0–29 110 23 133 
2017 0–29 111 23 134 
2018 0–29 111 23 134 
2019 0–29 111 23 134 
2020 0–29 111 23 134 
2012 30–49 455 44 499 
2013 30–49 467 45 512 
2014 30–49 481 46 527 
2015 30–49 494 48 542 
2016 30–49 509 49 558 
2017 30–49 525 51 576 
2018 30–49 541 52 593 
2019 30–49 556 54 610 
2020 30–49 572 55 627 
2012 50–64 769 39 808 
2013 50–64 791 40 831 
2014 50–64 813 41 854 
2015 50–64 834 42 876 
2016 50–64 855 43 898 
2017 50–64 875 44 919 
2018 50–64 897 45 942 
2019 50–64 921 46 967 
2020 50–64 946 48 994 
2012 65–74 686 6 692 
2013 65–74 723 6 729 
2014 65–74 757 7 764 
2015 65–74 792 7 799 
2016 65–74 827 7 834 
2017 65–74 859 8 867 
2018 65–74 896 8 904 
2019 65–74 927 8 935 
2020 65–74 959 8 967 
2012 75+ 680 0 680 
2013 75+ 737 0 737 
2014 75+ 800 0 800 
2015 75+ 868 0 868 
2016 75+ 942 0 942 
2017 75+ 1,027 0 1,027 
2018 75+ 1,117 0 1,117 
2019 75+ 1,222 0 1,222 
2020 75+ 1,340 0 1,340 
Source: AIHW analysis of ANZDATA Registry data. 
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Prevalence projection results  
Table E3: Projected prevalence counts from the ‘base’ model, the ‘stable incidence’ 
model and the ‘improving dialysis treatment outcomes’ model, total persons, 2012–2020 
Year Incident age group ‘Base’ model  ‘Stable incidence’ model ‘Improving dialysis treatment outcomes’ model 
2012 Total 20,968 20,769 20,987 
2013 Total 22,174 21,750 22,230 
2014 Total 23,412 22,735 23,523 
2015 Total 24,682 23,726 24,867 
2016 Total 25,983 24,720 26,259 
2017 Total 27,320 25,719 27,708 
2018 Total 28,696 26,724 29,216 
2019 Total 30,117 27,736 30,789 
2020 Total 31,589 28,756 32,437 
Percentage Increase(a)  59.6% 45.3% 63.8% 
(a) Percentage increases over the projection years were calculated using the last available registry data point (2011) as a base 
year. 
Source: AIHW analysis of ANZDATA Registry data. 
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Table E4: Projected prevalent counts from ‘base’ model, ‘stable incidence’ model and  
‘improving dialysis treatment outcomes’ model by incident age group, 2012–2020 
Year Incident age group ‘Base’ model  ‘Stable incidence’ model 
‘Improving dialysis 
treatment outcomes’ model  
2012 0–29 3,352  3,358  3,352  
2013 0–29 3,449  3,462  3,449  
2014 0–29 3,546  3,567  3,546  
2015 0–29 3,644  3,673  3,644  
2016 0–29 3,741  3,781  3,741  
2017 0–29 3,839  3,889  3,839  
2018 0–29 3,936  3,999  3,936  
2019 0–29 4,033  4,110  4,033  
2020 0–29 4,129   4,222  4,129  
2011–2020 percentage increase(a)  26.9% 29.7%  26.9%  
2012 30–49 6,576  6,555  6,576  
2013 30–49 6,878  6,831  6,878  
2014 30–49 7,192  7,112  7,192  
2015 30–49 7,516  7,400  7,516  
2016 30–49 7,851  7,695  7,851  
2017 30–49 8,199  7,996  8,199  
2018 30–49 8,558  8,302  8,558  
2019 30–49 8,928  8,613  8,928  
2020 30–49 9,307  8,928  9,307  
2011–2020 percentage increase(a) 48.2%  42.2%  48.2%  
2012 50–64 5,974  5,945  5,974  
2013 50–64 6,355  6,289  6,355  
2014 50–64 6,742  6,634  6,742  
2015 50–64 7,133  6,976  7,133  
2016 50–64 7,529  7,315  7,529  
2017 50–64 7,928  7,652  7,928  
2018 50–64 8,333  7,986  8,333  
2019 50–64 8,744  8,320  8,744  
2020 50–64 9,164  8,654  9,164  
2011–2020 percentage increase(a) 63.7%  54.6%  63.7%  
2012 65–74 3,053  3,013  3,061  
2013 65–74 3,273  3,192  3,296  
2014 65–74 3,497  3,373  3,542  
2015 65–74 3,722  3,556  3,797  
2016 65–74 3,949  3,739  4,060  
2017 65–74 4,176  3,920  4,329  
2018 65–74 4,405  4,102   4,608  
2019 65–74 4,632  4,279  4,891  
2020 65–74 4,858  4,454  5,179  
2011–2020 percentage increase(a) 71.4%  57.2%  82.7%  
2012 75+ 2,013  1,899  2,024  
2013 75+ 2,219  1,976  2,252  
2014 75+ 2,436  2,049  2,502  
2015 75+ 2,667  2,120  2,777  
2016 75+ 2,911  2,190  3,077  
2017 75+ 3,177  2,262  3,412  
2018 75+ 3,464  2,335  3,780  
2019 75+ 3,780  2,414  4,193  
2020 75+ 4,130  2,499  4,658  
2011–2020 percentage increase(a) 111.8%  37.0%  154.9%  
(a) Percentage increases over the projection years were calculated using linear registration with the last available registry data point (2011) as 
a base year. 
Source: AIHW analysis of ANZDATA Registry data. 
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Glossary 
chronic kidney disease (CKD) Refers to all kidney conditions where a person has 
evidence of kidney damage and/or reduced kidney 
function, lasting at least 3 months, regardless of the 
specific diagnosis of the disease or condition causing 
the disease. 
comorbidity When a person has 2 or more health problems at the 
same time. 
diabetes (diabetes mellitus) A chronic condition in which the body cannot 
properly use its main energy source, the sugar 
glucose. This is due to a relative or absolute 
deficiency in insulin, a hormone that is produced by 
the pancreas and helps glucose enter the body’s cells 
from the bloodstream and then be processed by them. 
Diabetes is marked by an abnormal build-up of 
glucose in the blood, and it can have serious short- 
and long-term effects. 
diabetic nephropathy Disease of the capillaries of the glomeruli (a 
component of the basic filtering unit in the kidney) 
caused by diabetes. 
dialysis An artificial method of removing waste substances 
from the blood and regulating levels of circulating 
chemicals—functions usually performed by the 
kidneys. 
end-stage kidney disease (ESKD) The most severe stage of chronic kidney disease. It 
occurs when kidney function has deteriorated so 
much that it is no longer sufficient to sustain life, and 
kidney replacement therapy (KRT) in the form of 
dialysis or kidney transplantation is required for the 
patient to survive.  
haemodialysis A form of dialysis where a machine is connected to a 
person’s bloodstream and then filters the blood 
externally to the body, removing water, excess 
substances and waste from the blood as well as 
regulating the levels of circulating chemicals. In doing 
this the machine takes on the role normally played by 
the kidneys. Haemodialysis is provided largely in 
hospitals or satellite dialysis units. 
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incidence The number of new cases (of an illness, disease or 
event) occurring during a given period. Compare 
with prevalence. 
incident patient A new (treated-ESKD) patient. Compare with 
prevalent patient. 
kidney replacement therapy (KRT)  Having a functional kidney transplant or receiving 
regular dialysis. 
kidney transplant A healthy kidney is taken from one person and 
surgically placed into someone with ESKD. The 
kidney can come from a live or deceased donor. 
Markov states Possible states (dialysis, transplant, death) in the 
Markov-model-based projection models used in this 
report.  
peritoneal dialysis A form of dialysis where a solution is pumped into 
the abdominal cavity, where the body’s own 
peritoneum ― the lining of that cavity― acts as a 
dialysis filter to remove waste products and water. 
pre-emptive transplant A transplant performed on a patient without prior 
dialysis treatment. 
prevalence The number or proportion (of cases, instances) 
present in a population at a given time. Compare with 
incidence. 
prevalent patient An existing (treated-ESKD) patient. Compare with 
incident patient. 
satellite dialysis unit A dialysis unit to provide dialysis away from a 
hospital. 
transition probability The likelihood of transitioning between Markov 
states, or remaining in the same state. For example, 
the likelihood of transitioning from dialysis treatment 
to death. 
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Projections of the prevalence of treated 
end-stage kidney disease in Australia
2012–2020
End-stage kidney disease (ESKD) is the most severe form 
of chronic kidney disease with patients usually requiring 
kidney replacement therapy in the form of dialysis or 
kidney transplantation to survive. 
Projections of the prevalence of treated end-stage kidney 
disease in Australia presents national level projections 
of the number of people receiving kidney replacement 
therapy for their ESKD for the period 2012 to 2020.  
This information is important for predicting the future 
burden of ESKD in Australia.
